Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin

AUTHORS

Mehdi Dehghani ORCID 1 , *

1 Assistant Professor, Section of Hematology and Oncology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

How to Cite: Dehghani M. Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin, Shiraz E-Med J. Online ahead of Print ; 9(1):42-44.

ARTICLE INFORMATION

Shiraz E-Medical Journal: 9 (1); 42-44
Published Online: January 1, 2008
Article Type: Case Report
Received: May 1, 2005
Accepted: September 2, 2007
READ FULL TEXT

Abstract

Hepatitis B virus asymptomatic carriers should receive treatment in certain conditions, such as prior to chemotherapy and organ transplantation. In these groups interferon alpha has limited efficacy or is even contraindicated. In contrast, lamivudine is highly effective in both preventing of and treat- ment of HBV reactivation in these immunosuppressed patients. Prevention of reactivation has better results than treating reactivation.

Full Text

Full text is available in PDF

© 2008, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: